Cybin (HELP) Capital Expenditures (2020 - 2025)
Cybin's (HELP) quarterly Capital Expenditures came in at -$383000.0 in Q4 2025, down 76.58% YoY from -$1.6 million in Q4 2024, and up 12.16% on a QoQ basis from -$436000.0 in Q3 2025.
Cybin (HELP) Capital Expenditures (2020 - 2025) Analysis & Trends
Cybin (HELP) has 6 years of Capital Expenditures data on file, last reported at -$383000.0 in Q4 2025.
- Quarterly Capital Expenditures fell 76.58% year-over-year to -$383000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.3 million (down 1446.03% YoY) and the FY2024 annual result came in at $15584.4, changed N/A from the prior year.
- Capital Expenditures improved to -$383000.0 in Q4 2025, from -$436000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $382930.4 in Q1 2024 to a low of -$436000.0 in Q3 2025.
- A 5-year average of -$81385.0 and a median of -$39862.8 in 2021 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2021 — Capital Expenditures jumped 74.72% — and 2022, when it slumped 503.42%.
- Tracing HELP's Capital Expenditures over 5 years: stood at -$17453.4 in 2021, then sank by 476.77% to -$100666.1 in 2022, then declined by 25.5% to -$126340.1 in 2023, then tumbled by 71.68% to -$216902.3 in 2024, then sank by 76.58% to -$383000.0 in 2025.
- The last three Capital Expenditures figures came in at -$383000.0 (Q4 2025), -$436000.0 (Q3 2025), and -$231000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Cybin | 417.29 Mn | 417.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -383,000.00 |
| Dec 31, 2025 | -383,000.00 |
| Sep 30, 2025 | -436,000.00 |
| Sep 30, 2025 | -436,000.00 |
| Jun 30, 2025 | -231,000.00 |
| Jun 30, 2025 | -231,000.00 |
| Dec 31, 2024 | -216,902.29 |
| Dec 31, 2024 | -216,902.29 |
| Mar 31, 2024 | 382,930.42 |
| Mar 31, 2024 | 382,930.42 |
| Dec 31, 2023 | -126,340.11 |
| Dec 31, 2023 | -126,340.11 |
| Feb 28, 2023 | 54,433.59 |
| Feb 28, 2023 | 54,433.59 |
| Sep 30, 2022 | -100,666.11 |
| Sep 30, 2022 | -100,666.11 |
| May 31, 2022 | -8,427.14 |
| May 31, 2022 | -8,427.14 |
| Feb 28, 2022 | 80,965.31 |
| Feb 28, 2022 | 80,965.31 |